MarginsXMarginsX
Home › Markets › Health Care › LNTH

Lantheus Holdings Inc. (LNTH)

LNTH trades on Nasdaq in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$101.72
+0.13% on the day
Market cap
$6.7B
Mid cap
Revenue · 2025
$1.5B
+0.5% on 2024
Net income · 2025
$233.6M
15.2% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1521036/000119312526073498/0001193125-26-073498-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerLNTH on Nasdaq
SectorHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
CountryUnited States
IPO year2015
SEC CIK0001521036
SEC industry codeIn Vitro & In Vivo Diagnostic Substances
Incorporated inDE

Financials · 2025

LineValue
Revenue$1.5B
Net income$233.6M
Operating income$310.8M
Net margin15.2%
Operating margin20.2%
Revenue growth+0.5%
Cash$359.1M
Total assets$2.2B
P/E (computed)28.5×
P/S (computed)4.3×

Warning signs

Cash runway
Cash-flow positive
$683.6M cash at September 30, 2026
Share count, 1 year
-1.4%
2025-11-03 to 2026-11-02 · -4.5% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$683.6M cash; operating cash flow $102.4M a quarter.Report 2026-09-30
Shares outstanding65,401,413 (2026-11-02); 66,311,779 a year earlier; 68,489,153 three years earlier.Cover page 2026-11-02
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-09
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$389.9M$22.4M$102.0M$683.6M$571.7M$1.6B10-Q 2026-11-05
Q2 2026
2026-06-30
$388.2M$75.0M$92.2M$593.3M$571.1M$1.6B10-Q 2026-08-06
Q1 2026
2026-03-31
$377.3M$118.4M$125.1M$498.6M$570.4M$1.5B10-Q 2026-05-07
Q4 2025
2025-12-31
$406.8M$54.1M$90.2M$359.1M$569.4M$1.5B10-K 2026-02-26
Q3 2025
2025-09-30
$384.0M$27.8M$105.3M$382.0M$568.8M$1.5B10-Q 2026-11-05
Q2 2025
2025-06-30
$378.0M$78.8M$87.1M$695.6M$567.6M$1.5B10-Q 2026-08-06
Q1 2025
2025-03-31
$372.8M$72.9M$107.6M$938.5M$566.8M$1.5B10-Q 2026-05-07
Q4 2024
2024-12-31
$391.1M-$11.8M$157.7M$912.8M$566.3M$1.5B10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32020-05-14
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-10
Latest proxyDEFA14A2026-10-02

Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+1.0%
1 month+1.6%
3 months+0.6%
Year to date+52.7%
1 year+91.2%
From 52-week high-8.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances

TickerCompanyPriceDayMarket cap
ORKAOruka Therapeutics Inc.$99.24-5.80%$6.7B
NEOGNeogen Corporation$10.88-3.12%$2.4B
CLDXCelldex Therapeutics Inc.$28.59-0.83%$2.2B
NTLAIntellia Therapeutics Inc.$9.86+1.65%$1.4B
IDXXIDEXX Laboratories Inc.$700.65-0.51%$55.2B
QDELQuidelOrtho Corporation$10.21-4.93%$700.5M
QUITAchieve Life Sciences Inc. Common Shares$6.06-4.11%$666.8M
NNNNAnbio Biotechnology$3.88+1.57%$558.3M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier